1TMO Stock Chart & Stats
€498.30
€7.90(1.61%)
At close: 4:00 PM EDT
€498.30
€7.90(1.61%)
Day’s Range― - ―
52-Week Range€351.00 - €817.00
Previous CloseN/A
Volume0.00
Average Volume (3M)17.00
Market Cap
€199.07B
Enterprise Value€228.94K
Total Cash (Recent Filing)€4.06B
Total Debt (Recent Filing)€42.55B
Price to Earnings (P/E)33.8
Beta0.49
Next Earnings
Oct 28, 2026EPS Estimate
5.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)18.62
Shares Outstanding369,747,280
10 Day Avg. Volume33
30 Day Avg. Volume17
Financial Highlights & Ratios
PEG Ratio4.54
Price to Book (P/B)4.08
Price to Sales (P/S)4.89
P/FCF Ratio34.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€528.09Price Target Upside5.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
EPS Forecast (FY)21.5
Revenue Forecast (FY)€40.99B
Bulls Say, Bears Say
Bulls Say
Recurring, Diversified Life-sciences Business ModelThermo Fisher’s broad offering spans research, diagnostics and biopharma manufacturing, while recurring consumables and services create repeat demand. Its installed base and cross-selling opportunities support customer retention and durable revenue visibility.
Strong Free Cash Flow GenerationRobust operating and free cash flow indicates strong earnings conversion and gives Thermo Fisher flexibility to fund research, acquisitions, debt service and shareholder returns. This supports resilience across changing laboratory and healthcare spending cycles.
Raised Growth Outlook With Expanding MarginsThe upgraded outlook reflects improving organic growth, acquisition contribution and operating leverage. Expected margin expansion suggests productivity and scale can offset mix pressures, supporting earnings growth beyond a single quarter.
Bears Say
Elevated Leverage And Financing CostsHigher leverage reduces financial flexibility and increases sensitivity to interest rates or weaker operating conditions. Financing costs also compete with investment and capital returns, potentially limiting strategic flexibility if end-market growth slows.
Margins And Returns Remain Below Prior PeaksAlthough profitability remains solid, sustained margin and return compression versus earlier periods indicates that mix, costs or normalization effects remain unresolved. Without further productivity gains, earnings growth may not fully translate into historical profitability levels.
Microbiology Divestiture Reduces Future ScaleSelling the microbiology business simplifies the portfolio and provides cash, but removes an established revenue stream from Specialty Diagnostics. Management expects the transaction to reduce 2026 revenue and create post-close EPS dilution.
Thermo Fisher News
1TMO FAQ
What was Thermo Fisher’s price range in the past 12 months?
Thermo Fisher lowest stock price was €351.00 and its highest was €817.00 in the past 12 months.
What is Thermo Fisher’s market cap?
Thermo Fisher’s market cap is €199.07B.
When is Thermo Fisher’s upcoming earnings report date?
Thermo Fisher’s upcoming earnings report date is Oct 28, 2026 which is in 66 days.
How were Thermo Fisher’s earnings last quarter?
Thermo Fisher released its earnings results on Jul 23, 2026. The company reported €5.206 earnings per share for the quarter, beating the consensus estimate of €4.937 by €0.268.
Is Thermo Fisher overvalued?
According to Wall Street analysts Thermo Fisher’s price is currently Undervalued.
Does Thermo Fisher pay dividends?
Thermo Fisher does not currently pay dividends.
What is Thermo Fisher’s EPS estimate?
Thermo Fisher’s EPS estimate is 5.53.
How many shares outstanding does Thermo Fisher have?
Thermo Fisher has 369,747,280 shares outstanding.
What happened to Thermo Fisher’s price movement after its last earnings report?
Thermo Fisher reported an EPS of €5.206 in its last earnings report, beating expectations of €4.937. Following the earnings report the stock price went up 10.385%.
Which hedge fund is a major shareholder of Thermo Fisher?
Currently, no hedge funds are holding shares in IT:1TMO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Thermo Fisher Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€528.09 (5.98% Upside)
€528.09 (5.98% Upside)
Blogger Sentiment
Bullish
IT:1TMO Sentiment 67%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €9.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Bullish
Bullish news 60%
Bearish news 40%
Bearish news 40%
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.40%
12-Months-Change
Fundamentals
Return on Equity
0.29%
Trailing 12-Months
Asset Growth
11.80%
Trailing 12-Months
Company Description
Thermo Fisher
Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company's reach extends across North America, Europe, Asia-Pacific, and other international markets. Its Life Sciences Solutions division furnishes researchers with essential reagents, state-of-the-art instruments, and consumables vital for biological and medical exploration, the development and manufacturing of therapeutics and vaccines, and the detection of infections and various diseases. This segment encompasses bioscience, genetic science, and bioproduction technologies, serving a broad spectrum of clients in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and governmental sectors. The Analytical Instruments segment delivers a variety of precision instruments, consumables, software, and support services to pharmaceutical, biotechnology, academic, governmental, environmental, and industrial research environments, as well as clinical laboratories. The Specialty Diagnostics segment offers an array of diagnostic tools, including liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, alongside calibrators, controls, protein detection assays, and accompanying instruments. This also features the creation and distribution of complete blood test systems to aid in the clinical diagnosis and monitoring of allergies, asthma, and autoimmune diseases. Furthermore, it provides dehydrated and prepared culture media, specimen collection and transport systems, related instrumentation and consumables, human leukocyte antigen (HLA) typing and testing crucial for the organ transplant sector, and other healthcare products. Lastly, the Laboratory Products and Biopharma Services segment supplies laboratory equipment, serves the research and safety markets through its channels, and offers extensive pharmaceutical services, encompassing clinical research support. The company's products and services are distributed through a dedicated direct sales team, customer service professionals, online commerce platforms, and a network of third-party distributors. Its recognized brands include Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. Thermo Fisher Scientific Inc. was established in 1956 and is headquartered in Waltham, Massachusetts.
1TMO Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational execution: double-digit reported revenue growth, a clean beat to prior guidance, margin expansion, robust free cash flow, successful acquisition integration, numerous product launches and an upward revision to full-year guidance. The primary negatives were modest and manageable: the planned microbiology divestiture (small near-term revenue and EPS drag and future dilution), lingering softness in certain end markets (academic/government and parts of China), some unfavorable product mix impacts, a reduced FX tailwind and elevated leverage. Overall, the positives in the quarter — including beats, guidance raise, margin expansion and strong cash generation — substantially outweigh the lowlights.View all IT:1TMO earnings summaries1TMO Revenue Breakdown
54.01% Laboratory Products and Biopharma Services
22.46% Life Sciences Solutions
17.40% Analytical Instruments
10.52% Specialty Diagnostics

1TMO Stock 12 Month Forecast
Average Price Target
€528.09
▲(5.98% Upside)











